The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2018 | The unmet needs in low-risk MDS
David Steensma
• 12 Sep 2018
Speaking from the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting, held in Houston, TX, David Steensma, MD, of the Dana-Farber Cancer Institute, Boston, MA, highlights the unmet needs in low-risk myelodysplastic syndromes (MDS) currently. Dr Steensma discusses relapse following hypomethylating agent treatment, transfusion-dependence and iron overload, and those with low neutrophil and platelet counts.
